INTERNATIONAL ISOTOPES REMAINS HOPEFUL FOR DE-CONVERSION FACILITY

International Isotopes remains hopeful that it will eventually secure enough contracts to move forward with its proposed uranium de-conversation facility in Hobbs, N.M., according to President and CEO Steve Laflin during an investor’s call yesterday. The company announced in its third quarter results last year that active design and construction for the facility needed to be put on hold after it could not secure financing without contract commitments. “While the three other commercial enrichment companies we were in discussions with years ago have not moved forward with their plans, neither have they canceled their projects,” Laflin said. “We remain confident that one or more of these new enrichment projects will come to fruition in the next several years. When they do, we will be ready to resume contract talks, admit our remaining facility capacity, obtain project financing, and proceed with the design and construction of the facility in Hobbes. In the meantime, we remain in a very fortunate position of being able to wait.” Laflin also highlighted the recent announcement from the Department of Energy that would allow GE Hitachi’s Global Laser Enrichment to build a facility that can re-enrich depleted uranium tails at its Paducah site as a potential partner that could use the Hobbs facility for de-conversion services for depleted tails resulting from the GLE process.

Included in the investor’s call were the preliminary financial results for 2013. The company suffered a net loss of $2.4 million, up ten percent from 2012, Laflin said, and its total revenue came in at $6.8 million, down about 10 percent from 2012. Much of the blame for the results was attributed to the poor performance of the company’s cobalt product technologies, but Laflin remained hopeful that this sector would bounce back in 2014. He anticipates a 30 percent increase in total revenue for 2014, as well as a positive cash flow balance for the year.  

More on This Topic


Centrus reports mixed results as HALEU market takes shape

Bethesda, Md.-based uranium broker Centrus Energy reported mixed results in its earnings for the third quarter, seeing a gain in its quarterly income, but a decrease in net revenue.

Net income for the third quarter ended Sept. 30 was $31.6 million, or about $1.53 a share, up from $3.9 million, or $0.21 a share, in the year-ago quarter. Centrus said in its Wednesday earnings report the near $28 million increase was driven by “a $46.4 million gain recognized from the fair value adjustment of warrant liabilities during the current period and an increase of $4.0 million in investment income.”

Quarterly revenue, on the other hand, was approximately $55.5 million, a drop from $74.9 million a year ago. Much of the revenue decrease came from Centrus’ low-enriched uranium (LEU) segment.

The company’s LEU segment was $31.8 million, a decrease from $44.8 million in the year-ago quarter. This was attributed to a drop in the volume of uranium sold. However, Centrus’ separative work units – or SWU – revenue increased to $14.1 million in this year’s quarter over last year’s quarter of $10.7 million.

Centrus’ other segment of technical solutions, which includes its high-assay low-enriched uranium (HALEU) work for the Department of Energy and other technical services, took a hit. The technical solutions segment was $23.7 million, down from $30.1 million in the year-ago quarter.

During the investor call held on Thursday morning, Centrus CEO Amir Vexler said the market demand for HALEU is growing. Much of Centrus’ current backlog and work is rooted in LEU, Vexler said, but the company has signed a handful of HALEU contracts with advanced reactor companies, such as Radiant Nuclear and Antares Nuclear.

“This market’s demand represents an incremental growth opportunity that continues to mature,” Vexler said during the call. “We have positioned ourselves to capitalize on this potential market, if and when it matures, to provide ourselves with further optionality. This optionality includes our flexibility to use plant HALEU capacity for various assays of LEU and LEU+.”

HALEU’s growing market demand comes as Centrus is now using its 16-centrifuge cascades to enrich HALEU for the commercial market, making it the first U.S.-owned commercial enricher since the gaseous diffusion days, Vexler said. Centrus has been contracted by DOE to build a demonstration HALEU program for several years.

Vexler touted the demonstration program as successful so far and is in discussions with DOE about “how to amend [it] and how to make a more wholesome agreement where this continues to serve the market.”

In This Issue

More on This Topic